Which is easier to confirm?

Bacterial overgrowth, and only relatively. It has a breath test with published thresholds, though specialists actively dispute whether that test should be used. Mast cell criteria require mediator measurements with strict sample handling and two competing criteria sets disagree on who qualifies.

Does the referral bias problem mean the link is not real?

No, and that is the opposite error. A number inflated by how a sample was collected is a number you cannot read as a population rate. It is not evidence that the association is absent. The honest position is that these two do turn up together in the clinics that see them, and nobody has established how often they turn up together in general.

What would make the connection more convincing?

A sample that was not selected for being complicated. Prevalence measured in a general population, rather than among people already referred for being hard to explain, would tell you something the clinic figures structurally cannot. That is the study to look for, and its absence is the reason the current numbers should be read as describing a clinic.

Is it SIBO or MCAS?

By BeatSIBO editorial team · Updated August 5, 2026

At a glance

What it is
SIBO
A test result about gas
MCAS
Criteria about mediator release
Scope
SIBO
Local to the small intestine
MCAS
Systemic
Measurable
SIBO
Yes, imperfectly
MCAS
Only during a reaction, with strict handling
Watch out for
SIBO
Contested thresholds
MCAS
Overlap figures from specialist clinics only

SIBO compared with MCAS, on the dimensions that separate them
Dimension	SIBO	MCAS
What it is	A test result about gas	Criteria about mediator release
Scope	Local to the small intestine	Systemic
Measurable	Yes, imperfectly	Only during a reaction, with strict handling
Watch out for	Contested thresholds	Overlap figures from specialist clinics only

The one that matters: Published figures linking these two come from populations referred for being hard to explain, which inflates any overlap you compute.

This pair comes with a statistical trap attached, and almost nothing written for patients mentions it.

What actually separates them

The short answer

Bacterial overgrowth is a test result about gas production in the small intestine. Mast cell activation syndrome is a criteria-based description of immune cells releasing mediators throughout the body. One is local and measurable, if imperfectly. The other is systemic and defined by criteria that specialists dispute.

Worth knowing before you read any further: patients raise these two together far less often than they raise mast cell activation alongside histamine intolerance, long COVID or dysautonomia. Hold that in mind when you meet a clinic page describing this particular pair as tightly linked.

The referral bias problem

The short answer

Prevalence figures connecting these two come from specialist clinic populations. Everyone in such a sample was referred for being difficult to explain. Two conditions will look strongly linked in that setting partly because having both is what got a person referred in the first place. The number describes the clinic, not the general population, and not you.

This is not a criticism of the clinicians who published those figures. A specialist clinic is where these patients are, so it is where the data comes from. The error is in reading a clinic co-occurrence rate as though it were a population rate, which is what happens every time one of those percentages gets quoted on a supplement page.

What is not settled here

Whether either of these conditions influences the other is unresolved. Mediator release plausibly affects gut motility. Altered gut populations plausibly affect mast cell activity. Both directions have advocates, neither has a study that settles it, and the confident versions you will find online are generally attached to a protocol for sale.

What the guideline says about symptoms

Pimentel M et al., American Journal of Gastroenterology 2020 Clinical guideline

No single symptom can be specifically attributed to overgrowth, and five of six recommendations rest on evidence graded very low quality by the authors themselves. If that is the state of the condition with a test, symptom-matching your way to a conclusion about a pair of overlapping conditions is not going to work.

What to do next

Ask which tests are proposed, what each can physically measure, and what a negative would rule out. Those questions have answers. The question of which of two contested labels applies to you frequently does not.

Common questions

Which is easier to confirm?: Bacterial overgrowth, and only relatively. It has a breath test with published thresholds, though specialists actively dispute whether that test should be used. Mast cell criteria require mediator measurements with strict sample handling and two competing criteria sets disagree on who qualifies.
Does the referral bias problem mean the link is not real?: No, and that is the opposite error. A number inflated by how a sample was collected is a number you cannot read as a population rate. It is not evidence that the association is absent. The honest position is that these two do turn up together in the clinics that see them, and nobody has established how often they turn up together in general.
What would make the connection more convincing?: A sample that was not selected for being complicated. Prevalence measured in a general population, rather than among people already referred for being hard to explain, would tell you something the clinic figures structurally cannot. That is the study to look for, and its absence is the reason the current numbers should be read as describing a clinic.